Clinical Trial Update: A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC [Phase 1, Phase 2]

View source ↗

Summary

This entry announces an ongoing Phase Ib/II trial of M701 for malignant pleural effusions caused by non-small cell lung cancer (stage IV), currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Effusion
• Non-small Cell Lung Cancer

Drugs mentioned

• M701

Snippet

Sponsor: Wuhan YZY Biopharma Co., Ltd. | Conditions: Malignant Pleural Effusions, NSCLC Stage IV | Phase 1, Phase 2 | Status: RECRUITING